# STROBE Statement—checklist of items that should be included in reports of observational studies

| Section/Item | Item No | Recommendation | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|--------------|---------|----------------|-------------------------------------|------------------------------|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 2/Line 5-8 | Patients and |
|               |         |                |                                     | Results/Whole Paragraph      |
| Introduction  |         |                |                                     |                              |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 2 /Line 27-44 and Page 3/Line 1-4 | Paragraph 1 and part of paragraph 2 |
| Objectives   | 3 | State specific objectives, including any prespecified hypotheses | Page 3/Line 4-7 | Part of paragraph 2 |
| Methods      |         |                |                                     |                              |
| Study design | 4 | Present key elements of study design early in the paper | Page 3/Line 11-19 | Patients/Paragraph 1 |
| Setting      | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 3/Line 11-19 | Patients/Paragraph 1 |
| Participants | 6 | (a) **Cohort study**—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up **Case-control study**—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls **Cross-sectional study**—Give the eligibility criteria, and the sources and methods of selection of participants (b) **Cohort study**—For matched studies, give matching criteria and number of exposed and unexposed **Case-control study**—For matched studies, give matching criteria and the number of controls per case | Page 3/Line 11-19 | Patients/Paragraph 1 |
| Variables    | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Page 3/Line 11-29 | Patients/Paragraph 1 and Gene mutation |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 3/Line 11-29 | Patients/Paragraph 1 and Gene mutation |
| Bias         | 9 | Describe any efforts to address potential sources of bias | This in a single center | This in a single center |
| Study size   | 10 | Explain how the study size was arrived at | Page 3/Line 11 | Patients/The first sentence. |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Not included in the article. | Not included in the article. |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | Page 3/Line 31-34 | Statistical analysis |
|---------------------|----|-------------------------------------------------------------------|-------------------|---------------------|
|                     |    | (b) Describe any methods used to examine subgroups and interactions | Page 3/Line 31-34 | Statistical analysis |
|                     |    | (c) Explain how missing data were addressed | Page 3/Line 17-18. Only | No missing data were used |
| (d) **Cohort study**—If applicable, explain how loss to follow-up was addressed | Page 3/Line 17-18. Only | Patients got the data needed in the study were analyzed. Others will be. |
| (e) **Case-control study**—If applicable, explain how matching of cases and controls was addressed | Page 3/Line 17-18. Only | Patients got the data needed in the study were analyzed. Others will be. |
| (f) **Cross-sectional study**—If applicable, describe analytical methods taking account of sampling strategy | Page 3/Line 17-18. Only | Patients got the data needed in the study were analyzed. Others will be. |
|                     |    | (e) Describe any sensitivity analyses | No sensitivity analyses. | No sensitivity analyses. |

**Results**

| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Page 3/Line 37-42 | In the section of "EGFR 19del subtypes" |
|--------------|-----|-------------------------------------------------------------------|-------------------|---------------------|
|              |    | (b) Give reasons for non-participation at each stage | Page 3/Line 37-38 | In the section of "EGFR" |
|              |    | (c) Consider use of a flow diagram | It was not necessary in the | It was not necessary in the |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Page 4/Line 1-12 | In the section of "Clinicopathological..." |
|              |    | (b) Indicate number of participants with missing data for each variable of interest | Page 3/Line 37-42; Page | In the section of "EGFR" |
|              |    | (c) **Cohort study**—Summarise follow-up time (eg, average and total amount) | The medium follow-up | The medium follow-up |
| Outcome data | 15* | **Cohort study**—Report numbers of outcome events or summary measures over time | Page 4/Line 18-36, 43-46; | Section "Clinical" |
|              |    | **Case-control study**—Report numbers in each exposure category, or summary measures of exposure | Not applicable. | Not applicable. |
|              |    | **Cross-sectional study**—Report numbers of outcome events or summary measures | Not applicable. | Not applicable. |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | No adjusted data in the article. | No adjusted data in the article. |
|              |    | (b) Report category boundaries when continuous variables were categorized | The survival were... | The survival were... |
|              |    | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Not included in the study. | Not included in the study. |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | No other analyses beyond | No other analyses beyond |

**Discussion**

| Key results | 18 | Summarise key results with reference to study objectives | Page 5/Line 29-31, 42; | In paragraph 2 and 3. |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 5/Line 43-44; Page 6/Line 13-15 | Paragraph 3/4. |
### Interpretation 20
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence

Page 5/Line 25-27, 35-4; 
Page 6/Line 1-11, 20-23
Paragraph 2/3/4 in "Discussion"

### Generalisability 21
Discuss the generalisability (external validity) of the study results

Page 6/Line 42-46
In "Conclusion"

### Funding 22
Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

Page 7/Line 7-9
In "Acknowledgment"

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plospath.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

**Article information:** http://dx.doi.org/10.21037/hiicr-19-359

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.*